Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 17;12(4):1612.
doi: 10.3390/jcm12041612.

Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments: Definition, Classification, and Diagnostic Pathways

Ciro Mauro  1 , Valentina Capone  1   2 , Rosangela Cocchia  1 , Filippo Cademartiri  3 , Ferdinando Riccardi  4 , Michele Arcopinto  5 , Maie Alshahid  6 , Kashif Anwar  6 , Mariano Carafa  7 , Andreina Carbone  8 , Rossana Castaldo  9 , Salvatore Chianese  1   2 , Giulia Crisci  5 , Roberta D'Assante  5 , Mariarosaria De Luca  5 , Monica Franzese  9 , Domenico Galzerano  6 , Vincenzo Maffei  10 , Alberto Maria Marra  5 , Alfredo Mazza  11 , Brigida Ranieri  9 , Anna D'Agostino  9 , Salvatore Rega  12 , Luigia Romano  13 , Sarah Scagliarini  4 , Chiara Sepe  14 , Olga Vriz  6 , Raffaele Izzo  2 , Antonio Cittadini  5 , Eduardo Bossone  12 , Andrea Salzano  9
Affiliations
Review

Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments: Definition, Classification, and Diagnostic Pathways

Ciro Mauro et al. J Clin Med. .

Abstract

Early detection and treatment of cancer have led to a noticeable reduction in both mortality and morbidity. However, chemotherapy and radiotherapy could exert cardiovascular (CV) side effects, impacting survival and quality of life, independent of the oncologic prognosis. In this regard, a high clinical index of suspicion is required by the multidisciplinary care team in order to trigger specific laboratory tests (namely natriuretic peptides and high-sensitivity cardiac troponin) and appropriate imaging techniques (transthoracic echocardiography along with cardiac magnetic resonance, cardiac computed tomography, and nuclear testing (if clinically indicated)), leading to timely diagnosis. In the near future, we do expect a more tailored approach to patient care within the respective community along with the widespread implementation of digital health tools.

Keywords: cancer therapy-related cardiovascular toxicity; cardio-oncology; chemotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Figure 1
Figure 1
Cardio-oncology: an integrated approach throughout cancer disease [7]. Abbreviations: CV, cardiovascular, CVD, cardiovascular disease.
Figure 2
Figure 2
An integrated multidisciplinary approach in management of cancer patients [7].
Figure 3
Figure 3
Echocardiography in the evaluation of chemotherapy CV side-effects. A 58-year-old female patient with known dyslipidemia and no other cardiovascular disease (Panel A). The patient was affected by stage IIIC high-grade serous ovarian cancer. She underwent four sessions of taxol/carboplatin protocol (S/P 4 cycles) before surgical debulking. After the last chemo session, she developed shortness of breath during mild physical effort which she never experienced before. At TTE, a significant reduction in LVEF and GLS compared with the baseline was seen (Panel B). The patient was put on metoprolol and Lisinopril. Atorvastatin and TTE were repeated after 1 month with evidence of mild improvement in LVEF and GLS (Panel C). Abbreviations: EF, left ventricular ejection function; GLS, global longitudinal strain; TEE, transthoracic echocardiography.
Figure 4
Figure 4
Management of cancer therapy-related CVD: a stepwise approach [2,7,36,38,82,83,84,85,86,87]. BNP = brain natriuretic peptide; CHT = chemotherapy; CMR = cardiac magnetic resonance; CT = computed tomography; CTA = computed tomography angiography; FFR = fractional flow reserve; CVD = cardiovascular disease; HF = heart failure; GLS = global longitudinal strain; LVD = left ventricular dysfunction; LVEF = left ventricular ejection function; NT-proBNP = N-terminal pro-brain natriuretic peptide; PH = pulmonary hypertension; RT = radiotherapy; VHD = valvular heart disease. * It is important to inquire about the presence of ferromagnetic components if the patient has breast tissue expanders. ** Including cardiologists, oncologists, radiotherapist oncologists, and hematologists.
See this image and copyright information in PMC

References

    1. Loud J., Murphy J. Cancer Screening and Early Detection in the 21st Century. Semin. Oncol. Nurs. 2017;33:121–128. doi: 10.1016/j.soncn.2017.02.002. - DOI - PMC - PubMed
    1. Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., Aboyans V., Asteggiano R., Galderisi M., Habib G., Lenihan D.J., Lip G.Y.H., Lyon A.R., et al. 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed under the Auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC) Eur. Heart J. 2016;37:2768–2801. doi: 10.1093/eurheartj/ehw211. - DOI - PubMed
    1. Daher I.N., Daigle T.R., Bhatia N., Durand J.-B. The Prevention of Cardiovascular Disease in Cancer Survivors. Tex. Heart Inst. J. 2012;39:190–198. - PMC - PubMed
    1. Plana J.C., Galderisi M., Barac A., Ewer M.S., Ky B., Scherrer-Crosbie M., Ganame J., Sebag I.A., Agler D.A., Badano L.P., et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J.—Cardiovasc. Imaging. 2014;15:1063–1093. doi: 10.1093/ehjci/jeu192. - DOI - PMC - PubMed
    1. Virani S.A., Dent S., Brezden-Masley C., Clarke B., Davis M.K., Jassal D.S., Johnson C., Lemieux J., Paterson I., Sebag I.A., et al. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. Can. J. Cardiol. 2016;32:831–841. doi: 10.1016/j.cjca.2016.02.078. - DOI - PubMed

LinkOut - more resources